Significant expansion of revenue and profit through drug launches and stabilization of the revenue base
First written in FY2017. 21 of 31 entries say "Advanced", first in FY2018. Latest entry: 2026-08-07.
No other company in this theme has enough history to compare yet.
- 2026-08-07SoftenedEarnings
「Consolidated business revenue for the cumulative first-quarter period amounted to ¥170 million, a decrease of ¥30 million year on year, due to the receipt of income from analysis services and other sources.」
Consolidated business revenue, including income from analysis services, declined by ¥30 million year on year. The disclosure indicates weakening on a quarterly basis rather than progress in revenue growth. - FY2026AdvancedAnnual report
「Consolidated business revenue for the fiscal year was ¥808 million, up ¥58 million from the previous fiscal year, due to income received from analysis services and other sources.」
Consolidated business revenue, centred on analysis services and other sources, was ¥808 million, up ¥58 million year on year. Revenue growth progressed, but the consolidated operating loss was ¥810 million, and profit has not yet stabilised. - FY2026-H1AdvancedAnnual report
「Consolidated business revenue for the interim consolidated accounting period was ¥431 million, up ¥206 million from the previous fiscal year, due to income received from analysis services and other sources.」
Consolidated business revenue from analysis services and other sources was ¥431 million for the interim period, up ¥206 million year on year. Revenue growth progressed, but the consolidated operating loss was ¥475 million, and profit has not yet stabilised. - FY2025AdvancedAnnual report
「Consolidated business revenue for the fiscal year was ¥750 million, up ¥139 million from the previous fiscal year, due to income received from analysis services and other sources.」
While targeting growth in revenue and profit and the stabilisation of the revenue base, consolidated business revenue increased by ¥139 million year on year. However, the consolidated operating loss was ¥797 million, and profit has not yet stabilised. - FY2025-H1WorsenedAnnual report
「Consolidated business revenue for the interim consolidated accounting period was ¥225 million, down ¥131 million from the previous fiscal year, due to income received from analysis services and other sources.」
While targeting future growth in revenue and profit and the stabilisation of the revenue base, business revenue for the interim consolidated accounting period declined by ¥131 million year on year, and the consolidated operating loss was ¥531 million. - FY2024WorsenedAnnual report
「Consolidated business revenue for the fiscal year was ¥610 million, down ¥524 million from the previous fiscal year, due to income received from analysis services and other sources.」
While targeting future growth in revenue and profit and the stabilisation of the revenue base, business revenue for the fiscal year declined by ¥524 million year on year, and the consolidated operating loss was ¥1,120 million. - FY2024-Q3WorsenedAnnual report
「b. Cancer precision medicine-related business Revenue from the business was ¥465 million, down ¥225 million year on year, due to income received from analysis services and other sources. The operating loss was ¥174 million, compared with a loss of ¥79 million in the previous fiscal year, mainly due to the recognition of research and development expenses and cost of sales related to analysis services, including genetic analysis services such as whole-exome sequencing, RNA sequencing and neoantigen analysis, liquid biopsy, TCR/BCR repertoire analysis and immune response analysis.」
Revenue from the cancer precision medicine-related business declined by ¥225 million year on year, while the operating loss widened from ¥79 million to ¥174 million. - FY2024-Q2WorsenedAnnual report
「b. Cancer precision medicine-related business Revenue from the business was ¥356 million, down ¥150 million year on year, due to income received from analysis services and other sources. The operating loss was ¥108 million, compared with a loss of ¥48 million in the previous fiscal year, mainly due to the recognition of research and development expenses and cost of sales related to analysis services, including genetic analysis services such as whole-exome sequencing, RNA sequencing and neoantigen analysis, liquid biopsy, TCR/BCR repertoire analysis and immune response analysis.」
Revenue from the cancer precision medicine-related business declined by ¥150 million year on year, while the operating loss widened from ¥48 million to ¥108 million. Recent performance under the policy of using analysis services as the revenue base has deteriorated. - FY2024-Q1WorsenedAnnual report
「Cancer precision medicine-related business Business revenue was ¥147 million, reflecting income received from analysis services and other sources, a decrease of ¥232 million year on year. Operating loss was ¥51 million, compared with operating profit of ¥9 million in the previous fiscal year, mainly due to research and development expenses and cost of sales related to analysis services, including genetic analysis services such as whole-exome analysis, RNA sequencing and neoantigen analysis, liquid biopsy, TCR/BCR repertoire analysis and immune response analysis.」
Revenue from the cancer precision medicine-related business declined from ¥380 million in the same period of the previous fiscal year to ¥147 million, and the business moved from operating income to an operating loss. Recent performance in expanding the revenue base has deteriorated. - FY2023AdvancedAnnual report
「Business revenue was ¥1,125 million, reflecting income received from commissioned testing services and other sources, a decrease of ¥29 million year on year. Operating loss was ¥34 million, compared with a loss of ¥48 million in the previous fiscal year, mainly due to research and development expenses and cost of sales related to analysis services, including genetic analysis services such as whole-exome analysis, RNA sequencing and neoantigen analysis, liquid biopsy, TCR/BCR repertoire analysis and immune response analysis.」
Annual business revenue in the cancer precision medicine-related business was ¥1,125 million, a decrease year on year, while operating loss narrowed from ¥48 million to ¥34 million. - FY2023-Q3AdvancedAnnual report
「b. Cancer precision medicine-related business Business revenue was ¥691 million, reflecting income received from commissioned testing services and other sources, an increase of ¥354 million year on year. Operating loss was ¥79 million, compared with a loss of ¥126 million in the previous fiscal year, mainly due to research and development expenses and cost of sales related to analysis services, including genetic analysis services such as whole-exome analysis, RNA sequencing and neoantigen analysis, liquid biopsy, TCR/BCR repertoire analysis and immune response analysis.」
Business revenue in the cancer precision medicine-related business increased year on year to ¥691 million, while operating loss narrowed from ¥126 million to ¥79 million. - FY2023-Q2AdvancedAnnual report
「b. Cancer precision medicine-related business Business revenue was ¥506 million, reflecting income received from analysis services and other sources, an increase of ¥263 million year on year. Operating loss was ¥48 million, compared with a loss of ¥62 million in the previous fiscal year, mainly due to research and development expenses and cost of sales related to analysis services, including genetic analysis services such as whole-exome analysis, RNA sequencing and neoantigen analysis, liquid biopsy, TCR/BCR repertoire analysis and immune response analysis.」
Business revenue from analysis services and other sources in the cancer precision medicine-related business reached ¥506 million, an increase of ¥263 million year on year. Operating loss also narrowed from ¥62 million in the previous fiscal year to ¥48 million. - FY2023-Q1AdvancedAnnual report
「Cancer precision medicine-related business Business revenue was ¥380 million, reflecting income received from analysis services and other sources, an increase of ¥284 million year on year. Operating profit was ¥9 million, compared with an operating loss of ¥33 million in the previous fiscal year, mainly due to research and development expenses and cost of sales related to analysis services, including genetic analysis services such as whole-exome analysis, RNA sequencing and neoantigen analysis, liquid biopsy, TCR/BCR repertoire analysis and immune response analysis.」
In the cancer precision medicine-related business, business revenue reached ¥380 million and the company shifted from an operating loss in the previous fiscal year to operating profit of ¥9 million. The results demonstrate specific progress in monetizing the analysis services and improving the revenue base. - FY2022AdvancedAnnual report
「b. Cancer precision medicine-related business Business revenue was ¥1,154 million, reflecting income received from commissioned testing services and other sources, an increase of ¥883 million year on year. Operating loss was ¥48 million, compared with a loss of ¥293 million in the previous fiscal year, mainly due to research and development expenses and cost of sales related to analysis services, including genetic analysis services such as whole-exome analysis, RNA sequencing and neoantigen analysis, liquid biopsy, TCR/BCR repertoire analysis and immune response analysis.」
Annual business revenue in the cancer precision medicine-related business reached ¥1,154 million, an increase of ¥883 million year on year. Operating loss also narrowed to ¥48 million, indicating progress in monetizing the analysis services and reducing losses. - FY2022-Q3AdvancedAnnual report
「Business revenue was ¥336 million, reflecting income received from commissioned testing services and other sources, an increase of ¥149 million year on year. Operating loss was ¥126 million, compared with a loss of ¥233 million in the previous fiscal year, mainly due to research and development expenses and cost of sales related to analysis services, including genetic analysis services such as whole-exome analysis, RNA sequencing and neoantigen analysis, liquid biopsy, TCR/BCR repertoire analysis and immune response analysis.」
Business revenue in the cancer precision medicine-related business increased year on year to ¥336 million, while operating loss narrowed from ¥233 million to ¥126 million. Monetization of the analysis services and reduction of losses are progressing. - FY2022-Q2AdvancedAnnual report
「b. Cancer precision medicine-related business Business revenue was ¥242 million, reflecting income received from analysis services and other sources, an increase of ¥126 million year on year. Operating loss was ¥62 million, compared with a loss of ¥148 million in the previous fiscal year, mainly due to research and development expenses and cost of sales related to analysis services, including genetic analysis services such as whole-exome analysis, RNA sequencing and neoantigen analysis, liquid biopsy, TCR/BCR repertoire analysis and immune response analysis.」
Business revenue from analysis services and other sources in the cancer precision medicine-related business increased ¥126 million year on year to ¥242 million, while operating loss narrowed from ¥148 million in the previous fiscal year to ¥62 million. - FY2022-Q1AdvancedAnnual report
「b. Cancer precision medicine-related business Business revenue was ¥95 million, reflecting income received from analysis services and other sources, an increase of ¥48 million year on year. Operating loss was ¥33 million, compared with a loss of ¥73 million in the previous fiscal year, mainly due to research and development expenses and cost of sales related to analysis services, including genetic analysis services such as whole-exome analysis, RNA sequencing and neoantigen analysis, liquid biopsy, TCR/BCR repertoire analysis and immune response analysis.」
Business revenue in the cancer precision medicine-related business increased year on year to ¥95 million, while operating loss narrowed from ¥73 million to ¥33 million. - FY2021-Q3AdvancedAnnual report
「b. Cancer precision medicine-related business Business revenue was ¥187 million, reflecting income received from commissioned testing services and other sources, an increase of ¥38 million year on year. Operating loss was ¥233 million, compared with a loss of ¥312 million in the previous fiscal year, mainly due to research and development expenses and cost of sales related to analysis services, including genetic analysis services such as whole-exome sequencing, RNA sequencing and neoantigen analysis, liquid biopsy, TCR/BCR repertoire analysis and immune response analysis.」
Business revenue in the cancer precision medicine-related business was ¥187 million from commissioned testing and other sources, an increase year on year. Operating loss also narrowed from ¥312 million to ¥233 million. - FY2021-Q2AdvancedAnnual report
「b. Cancer precision medicine-related business Business revenue was ¥116 million, reflecting income received from commissioned testing services and other sources, an increase of ¥20 million year on year. Operating loss was ¥148 million, compared with a loss of ¥211 million in the previous fiscal year, mainly due to research and development expenses and cost of sales related to analysis services, including genetic analysis services such as whole-exome analysis, RNA sequencing and neoantigen analysis, liquid biopsy, TCR/BCR repertoire analysis and immune response analysis.」
Business revenue in the cancer precision medicine-related business was ¥116 million, an increase year on year. Operating loss also narrowed from the previous fiscal year. - FY2021-Q1RestatedAnnual report
「Cancer precision medicine-related business Business revenue was ¥47 million, reflecting income received from commissioned testing services and other sources, a decrease of ¥1 million year on year. Operating loss was ¥73 million, compared with a loss of ¥108 million in the previous fiscal year, mainly due to research and development expenses and cost of sales related to analysis services, including genetic analysis services such as whole-exome sequencing, RNA sequencing and neoantigen analysis, liquid biopsy, TCR/BCR repertoire analysis and immune response analysis.」
The cancer precision medicine-related business recorded revenue from commissioned testing, and its operating loss narrowed year on year, although business revenue declined slightly. - FY2020AdvancedAnnual report
「Business revenue was ¥210 million, reflecting income received from commissioned testing services and other sources, an increase of ¥134 million year on year.」
Annual business revenue from commissioned testing services and other sources in the cancer precision medicine-related business reached ¥210 million, an increase of ¥134 million year on year. The annual results updated the company’s policy of making analysis and testing services a revenue base. - FY2020-Q3AdvancedAnnual report
「Cancer precision medicine-related business Business revenue was ¥148 million, reflecting income received from commissioned testing services and other sources, an increase of ¥104 million year on year.」
Cumulative business revenue from commissioned testing services and other sources in the cancer precision medicine-related business reached ¥148 million, an increase of ¥104 million year on year. - FY2020-Q2AdvancedAnnual report
「Cancer precision medicine-related business Business revenue was ¥96 million, reflecting income received from commissioned testing services and other sources, an increase of ¥73 million year on year.」
Cumulative business revenue from commissioned testing services in the cancer precision medicine-related business reached ¥96 million, up from the previously reported ¥49 million, demonstrating progress in monetizing the analysis and testing services. - FY2020-Q1AdvancedAnnual report
「Business revenue was ¥49 million, reflecting income received from commissioned testing services and other sources, an increase of ¥36 million year on year.」
The cancer precision medicine-related business recorded ¥49 million in business revenue from commissioned testing services, updating the results of efforts to establish analysis and testing services as a future revenue source. - FY2019-Q3AdvancedAnnual report
「Business revenue was ¥44 million, reflecting income received from commissioned testing services and other sources.」
For the cancer precision medicine-related business, cumulative business revenue from commissioned testing services and other sources increased from the previously reported ¥22 million to ¥44 million. - FY2019-Q2AdvancedAnnual report
「Cancer precision medicine-related business Business revenue was ¥22 million, reflecting income received from commissioned testing services and other sources.」
The cancer precision medicine-related business recorded ¥22 million in business revenue from commissioned testing services, demonstrating results from the analysis and testing services previously identified as future revenue sources. However, the business also recorded an operating loss of ¥483 million. - FY2018AdvancedAnnual report
「As efforts in cancer personalized medicine advance, we will generate revenue from commissioned testing services, including detailed genetic analysis of cancer cells, such as whole-exome, RNA sequencing and neoantigen analyses; liquid biopsy analysis services for early detection of cancer cells in blood; TCR/BCR repertoire analysis services; and immune response analysis services.」
In addition to product launches and royalties, multiple cancer precision medicine analysis services were specifically added as future sources of revenue and profit growth and greater stability in the revenue base. - FY2017First statedAnnual report
「If we launch a cancer treatment ourselves in the future, we will record sales revenue from the pharmaceutical product. If a partner launches a cancer treatment, we will record royalty revenue. Revenue and profit are expected to increase significantly, while the revenue base is expected to become more stable.」
Future revenue and profit growth and greater stability in the revenue base are expected through sales revenue from products launched in-house and royalty revenue from products launched by partners.